JP2015522539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522539A5 JP2015522539A5 JP2015512695A JP2015512695A JP2015522539A5 JP 2015522539 A5 JP2015522539 A5 JP 2015522539A5 JP 2015512695 A JP2015512695 A JP 2015512695A JP 2015512695 A JP2015512695 A JP 2015512695A JP 2015522539 A5 JP2015522539 A5 JP 2015522539A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- bone
- fgf21 protein
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 44
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 20
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 206010065687 Bone loss Diseases 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 230000011164 ossification Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000010392 Bone Fractures Diseases 0.000 claims description 7
- 208000006386 Bone Resorption Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 230000010256 bone deposition Effects 0.000 claims description 4
- 230000018678 bone mineralization Effects 0.000 claims description 4
- 230000024279 bone resorption Effects 0.000 claims description 4
- 239000004053 dental implant Substances 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 4
- 206010017076 Fracture Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646974P | 2012-05-15 | 2012-05-15 | |
| US61/646,974 | 2012-05-15 | ||
| US201361786939P | 2013-03-15 | 2013-03-15 | |
| US61/786,939 | 2013-03-15 | ||
| PCT/US2013/040275 WO2013173158A1 (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522539A JP2015522539A (ja) | 2015-08-06 |
| JP2015522539A5 true JP2015522539A5 (OSRAM) | 2016-06-23 |
Family
ID=48483225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512695A Withdrawn JP2015522539A (ja) | 2012-05-15 | 2013-05-09 | 線維芽細胞増殖因子２１タンパク質の治療目的の使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150141335A1 (OSRAM) |
| EP (1) | EP2852398A1 (OSRAM) |
| JP (1) | JP2015522539A (OSRAM) |
| KR (1) | KR20150002801A (OSRAM) |
| CN (1) | CN104302311A (OSRAM) |
| AU (1) | AU2013263188A1 (OSRAM) |
| BR (1) | BR112014028413A2 (OSRAM) |
| CA (1) | CA2869320A1 (OSRAM) |
| CL (1) | CL2014002846A1 (OSRAM) |
| CO (1) | CO7131381A2 (OSRAM) |
| EA (1) | EA201491856A1 (OSRAM) |
| HK (1) | HK1202800A1 (OSRAM) |
| IL (1) | IL235482A0 (OSRAM) |
| MA (1) | MA37506B1 (OSRAM) |
| MX (1) | MX2014013913A (OSRAM) |
| PE (1) | PE20142432A1 (OSRAM) |
| PH (1) | PH12014502537A1 (OSRAM) |
| SG (1) | SG11201407655TA (OSRAM) |
| TN (1) | TN2014000409A1 (OSRAM) |
| WO (1) | WO2013173158A1 (OSRAM) |
| ZA (1) | ZA201407532B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016039339A1 (ja) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108324928B (zh) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子-5在促骨折愈合中的应用 |
| EP3935075A4 (en) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| KR20240034235A (ko) | 2021-07-14 | 2024-03-13 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 대사 장애를 위한 융합 폴리펩타이드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101476472B1 (ko) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
-
2013
- 2013-05-09 CA CA2869320A patent/CA2869320A1/en not_active Abandoned
- 2013-05-09 EA EA201491856A patent/EA201491856A1/ru unknown
- 2013-05-09 AU AU2013263188A patent/AU2013263188A1/en not_active Abandoned
- 2013-05-09 EP EP13724685.6A patent/EP2852398A1/en not_active Withdrawn
- 2013-05-09 CN CN201380025338.6A patent/CN104302311A/zh active Pending
- 2013-05-09 WO PCT/US2013/040275 patent/WO2013173158A1/en not_active Ceased
- 2013-05-09 HK HK15103356.5A patent/HK1202800A1/xx unknown
- 2013-05-09 MX MX2014013913A patent/MX2014013913A/es unknown
- 2013-05-09 SG SG11201407655TA patent/SG11201407655TA/en unknown
- 2013-05-09 MA MA37506A patent/MA37506B1/fr unknown
- 2013-05-09 US US14/399,037 patent/US20150141335A1/en not_active Abandoned
- 2013-05-09 PE PE2014001980A patent/PE20142432A1/es not_active Application Discontinuation
- 2013-05-09 KR KR1020147031701A patent/KR20150002801A/ko not_active Withdrawn
- 2013-05-09 BR BR112014028413A patent/BR112014028413A2/pt not_active IP Right Cessation
- 2013-05-09 JP JP2015512695A patent/JP2015522539A/ja not_active Withdrawn
-
2014
- 2014-09-30 TN TNP2014000409A patent/TN2014000409A1/fr unknown
- 2014-10-16 ZA ZA2014/07532A patent/ZA201407532B/en unknown
- 2014-10-22 CL CL2014002846A patent/CL2014002846A1/es unknown
- 2014-11-03 IL IL235482A patent/IL235482A0/en unknown
- 2014-11-14 CO CO14252512A patent/CO7131381A2/es unknown
- 2014-11-14 PH PH12014502537A patent/PH12014502537A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2015009991A8 (en) | Methods, systems, and compositions for promoting bone growth | |
| WO2003094835A3 (en) | Fgf variants and methods for use thereof | |
| JP2014530220A5 (OSRAM) | ||
| DE502007002101D1 (de) | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen | |
| EA201490521A1 (ru) | Варианты фактора роста фибробластов 21 | |
| MX2012007052A (es) | Metodo para tratar fibrilacion atrial. | |
| JP2013231087A5 (OSRAM) | ||
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| WO2014110353A8 (en) | Notch ligand bound biocompatible substrates and their use in bone formation | |
| JP2017105861A5 (OSRAM) | ||
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
| NZ617397A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| MY169687A (en) | Component and method for treating viral disease | |
| EA201401155A1 (ru) | Препарат и способ профилактики и лечения атипичного остеопороза | |
| NZ592613A (en) | Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| WO2007112001A3 (en) | Compositions and methods for treating myocardial infarction | |
| ATE541567T1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten | |
| EA201401157A1 (ru) | Препарат и способ профилактики и лечения остеопороза и переломов костей | |
| AU2014230304A8 (en) | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor | |
| BRPI0507302A (pt) | método e composições para o tratamento da lipodistrofia | |
| RU2013144683A (ru) | Хелат бисглицината железа для использования в лечении анемии | |
| ZA202201789B (en) | Solid oral dosage form comprising naproxen and vitamin b6 |